Results 91 to 100 of about 42,337 (292)

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

The myelodysplastic syndrome. [PDF]

, 1989
D.A.G. Galton
openalex   +1 more source

Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T

British Journal of Haematology, EarlyView.
We applied three major comorbidity scoring systems—CIRS, HCT‐CI, and Severe4—to a cohort of 379 patients with LBCL treated with CAR‐T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR‐T treatment, including the ...
Eugenio Galli, Roberta Di Blasi, Ilaria Pansini, Caterina Cristinelli, Come Bommier, Ilenia De Bernardis, Alessandro Corrente, Marcello Viscovo, Luca Montini, Patrizia Chiusolo, Stefan Hohaus, Federica Sorà, Catherine Thieblemont, Simona Sica   +13 more
wiley   +1 more source

Pyogenic abscesses in the myelodysplastic syndrome. [PDF]

, 1989
Patrick Williamson, David Oscier, G J Mufti, Terry J. Hamblin   +3 more
openalex   +1 more source

Low rates of endothelial cell dysfunction and transplant‐related mortality in 537 children receiving fludarabine–treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group

British Journal of Haematology, EarlyView.
Thomas Altmann, Kanchan Rao, Ramya Hanasoge‐Nataraj, Katharine Patrick, Ben Carpenter, Rachael Hough, Anna‐Maria Ewins, Sanjay Tewari, Oana Mirci‐Danicar, Mary Slatter, Robert Wynn, Su Han Lum   +11 more
wiley   +1 more source

Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment

Biomedicines
Myelodysplastic syndromes represent a group of hematological neoplastic diseases caused by defective stem cells causing cytopenia and abnormal hematopoiesis. More than 30% of myelodysplastic syndrome cases develop into acute myeloid leukemia. An analysis
Fabio Stagno, Giuseppe Mirabile, Patricia Rizzotti, Adele Bottaro, Antonio Pagana, Sebastiano Gangemi, Alessandro Allegra   +6 more
doaj   +1 more source

Mutations of N‐ras Oncogene in Myelodysplastic Syndromes and Lcukemias Detected by Polymerase Chain Reaction [PDF]

, 1989
Hiroyuki Mano, Fuyuki Ishikawa, Hisamaru Hirai, Fumimaro Takaku   +3 more
openalex   +1 more source

ZIP10 as a potential therapeutic target in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Increased intracellular zinc levels in acute myeloid leukaemia blasts with upregulated expression of zinc influx transporters ZIP6 and ZIP10. Targeting ZIP10 with a surface antibody represents a potential therapeutic strategy. Created in BioRender. Rolles, B. (2025) https://BioRender.com/bwrtof1.
Benjamin Rolles, Nicolas Chatain, Richard Görg, Margherita Vieri, Nora Tillmann‐Tröster, Marcel G. Bourgeois, Deborah Christen, Jeanette Walter, Addison C. Hillerbrand, Kyle A. Romine, Kathryn M. Taylor, Jens Bertram, Edgar Jost, Steffen Koschmieder, Fabian Beier, Maximilian Stahl, Tim H. Brümmendorf, Lothar Rink, Inga Wessels   +18 more
wiley   +1 more source

Validation of survival‐predictive models in myelodysplastic syndromes [PDF]

, 1989
Miguel Á. Sanz, José Ignacio Lorenzo, Guillermo Sanz, Sonia García-Merino, Victoria Amigó, Teresa Vallespı́, Marta Torrabadella, M.C. Cañizo, Jesús F. San Miguel   +8 more
openalex   +1 more source

Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT

British Journal of Haematology, EarlyView.
Atte K. Lahtinen, Maarja Karu, Jessica R. Koski, Jarmo Ritari, Kati Hyvärinen, Satu Koskela, Julia Nihtilä, Jukka Partanen, Kim Vettenranta, Minna Koskenvuo, Riitta Niittyvuopio, Urpu Salmenniemi, Maija Itälä‐Remes, Kirsi Jahnukainen, Outi Kilpivaara, Ulla Wartiovaara‐Kautto   +15 more
wiley   +1 more source